GlobeNewswire Inc.··Trogenix Ltd.Trogenix Advances Glioblastoma Gene Therapy as First Patient Dosed in Phase I/II Trial
Trogenix begins first-patient dosing in Phase I/II trial of TGX-007 gene therapy for glioblastoma, backed by preclinical data showing 83% tumor eradication with no toxicity.
LLYclinical trialgene therapy